What is the recommended hepatitis B post‑exposure prophylaxis based on the source's HBsAg status and the recipient's vaccination and anti‑HBs antibody levels?

Hepatitis B Post-Exposure Prophylaxis

Post-exposure prophylaxis for hepatitis B depends on the exposed person's vaccination history, documented anti-HBs response, and the source patient's HBsAg status—with unvaccinated individuals requiring both HBIG and vaccine series when exposed to HBsAg-positive sources, while previously vaccinated responders need minimal or no intervention. 1

Algorithm Based on Vaccination Status and Source HBsAg Status

Unvaccinated or Incompletely Vaccinated Person

• HBsAg-positive source: Administer hepatitis B immune globulin (HBIG) 0.06 mL/kg intramuscularly plus initiate the complete hepatitis B vaccine series immediately. 1

• HBsAg-negative source: Initiate the hepatitis B vaccine series only; no HBIG required. 1

• Source unknown or unavailable for testing:

  • If the source is from a high-risk population, treat as if HBsAg-positive (HBIG + vaccine series). 1
  • Otherwise, initiate vaccine series without HBIG. 1

Previously Vaccinated Person with Known Adequate Response

• Any source HBsAg status: No post-exposure prophylaxis required if the person previously documented anti-HBs ≥10 mIU/mL after completing the primary vaccine series. 1, 2

• Immunocompetent individuals who achieved protective antibody levels retain long-term immunologic memory and protection even if circulating anti-HBs titers decline below 10 mIU/mL years later. 2

Previously Vaccinated Person with Unknown or Inadequate Response

• Test the exposed person for anti-HBs immediately: 1

  • If anti-HBs ≥10 mIU/mL: No treatment necessary regardless of source status. 1, 2

  • If anti-HBs <10 mIU/mL and source is HBsAg-positive: Administer HBIG × 1 dose plus one booster dose of hepatitis B vaccine. 1

  • If anti-HBs <10 mIU/mL and source is HBsAg-negative: Administer one booster dose of vaccine and recheck titer in 1–2 months. 1

Known Vaccine Non-Responder (anti-HBs <10 mIU/mL after two complete vaccine series)

• HBsAg-positive source:

  • Preferred approach: Administer HBIG × 1 dose and reinitiate a complete vaccine series if the person has not yet completed a second three-dose series. 1
  • Alternative for confirmed non-responders (failed two complete series): Administer HBIG × 2 doses separated appropriately. 1

• HBsAg-negative source: No treatment required. 1

• Source unknown but high-risk: Treat as if source were HBsAg-positive. 1

Critical Timing Considerations

• HBIG and vaccine should be administered as soon as possible after exposure, ideally within 24 hours, but prophylaxis may still be effective if given within 7 days for percutaneous or mucosal exposures. 3

• Post-vaccination serologic testing (anti-HBs) should be performed 1–2 months after the last vaccine dose to document response; testing cannot accurately assess vaccine response if HBIG was administered within the preceding 3–4 months. 1, 2

Special Populations and Nuances

• Persons previously infected with HBV (positive anti-HBc or prior HBsAg-positive status) are immune to reinfection and require no post-exposure prophylaxis. 1

• Immunocompromised individuals (HIV-infected, hemodialysis patients, chemotherapy recipients, transplant recipients) may have suboptimal vaccine responses and should undergo anti-HBs testing after exposure even if previously vaccinated; annual anti-HBs monitoring may be warranted in these populations. 1, 2

• Healthcare personnel and public safety workers should have documented anti-HBs levels on file to expedite post-exposure management decisions. 1, 4

Common Pitfalls to Avoid

• Do not confuse anti-HBc with anti-HBs: Anti-HBc indicates prior natural infection and is not produced by vaccination; a negative anti-HBc in a vaccinated person is expected and reassuring. 2

• Do not withhold prophylaxis while awaiting source testing results: If the source is high-risk or unavailable, initiate prophylaxis immediately and adjust if source testing later returns negative. 1

• Do not assume waning anti-HBs titers indicate loss of protection: Immunocompetent vaccine responders retain immunologic memory for decades; routine booster doses are not recommended. 2, 5

• Do not administer HBIG and vaccine at the same anatomic site: Use separate injection sites to avoid interference, although HBIG does not diminish vaccine immunogenicity when given concurrently. 3

• Approximately 5–10% of healthy vaccine recipients fail to achieve protective anti-HBs levels after the primary series; these non-responders require a second complete vaccine series and, if still non-responsive, should be counseled on the need for HBIG after future exposures. 2, 5